OnCo

Stay in the loop

Leave your email and OnCo will write when something big changes in cancer research. No spam, one click to unsubscribe.

Email updates open shortly. Until then, press Watch on any page to keep it on your list.

drugsTreatmentApproved2021🇨🇳

Pamiparib

aka BGB-290

Pamiparib is an oral parp inhibitor from BeiGene, in registered phase 3 trials for ovarian cancer.